{"answer":{"query":"xeljanz","resolved_as":"name","packages":12,"applications":["NDA203214","NDA208246","NDA213082"],"identity":{"application_numbers":["NDA203214","NDA208246","NDA213082"],"marketing_categories":["NDA"],"labelers":[{"text":"PFIZER LABORATORIES DIV PFIZER INC","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED, EXTENDED RELEASE","untrusted":true},{"text":"TABLET, FILM COATED","untrusted":true},{"text":"SOLUTION","untrusted":true}],"marketing_start":{"earliest":"2012-11-09","latest":"2021-02-08","packages_with_a_start_date":5}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":12,"negotiated_price_ends":null,"rows":[{"ndc":"00069050114","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069050130","name":{"text":"XELJANZ TOFACTINIB 11MG ER TABLET","untrusted":true},"class":"B","nadac_per_unit":207.89771,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069050230","name":{"text":"XELJANZ XR 22MG TAB 1X30 BTL US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100101","name":{"text":"XELJANZ TOFACTINIB 5MG TABLET","untrusted":true},"class":"B","nadac_per_unit":73.77164,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100102","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100103","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100201","name":{"text":"XELJANZ 10MG X 60 TAB US","untrusted":true},"class":"B","nadac_per_unit":103.93842,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100202","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069100203","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069102901","name":{"text":"XELJANZ 1MG/ML ORSOL 1X240ML PBTL US (Inner Pack)","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069102902","name":{"text":"XELJANZ 1MG/ML ORSOL 1X240ML PBTL US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"63539050114","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"generic_entry":[{"application":"NDA203214","date":"2028-08-21","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"exclusivity","ref":"PED","productNo":"001"},"latest_patent_expiry":"2026-06-08","latest_exclusivity_expiry":"2028-08-21","dated_barriers":6,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":1,"exclusivities_listed":2,"fact_id":"a167455f17fd58fff081413b"},{"application":"NDA208246","date":"2034-09-14","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10639309*PED","productNo":"002"},"latest_patent_expiry":"2034-09-14","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":12,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":4,"exclusivities_listed":0,"fact_id":"a7aadfe28d59dc11fcfa79de"},{"application":"NDA213082","date":"2028-08-21","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"exclusivity","ref":"PED","productNo":"001"},"latest_patent_expiry":"2026-06-08","latest_exclusivity_expiry":"2028-08-21","dated_barriers":4,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":1,"exclusivities_listed":2,"fact_id":"44c6be50d91bb2f62c83c236"}],"label_history":{"events_total":54,"non_cmc_events":53,"counts_by_class":{"LABELING":31,"EFFICACY":19,"REMS":3},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA203214","submission_no":42,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-09-16","documents":[{"type":"Letter","date":"2026-09-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203214Orig1s042, 208246Orig1s028, 213082Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-22","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf","untrusted":true}}],"fact_id":"ba4c2b1ad81032eeccb6c0e1"},{"application":"NDA208246","submission_no":28,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-09-16","documents":[{"type":"Letter","date":"2026-09-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203214Orig1s042, 208246Orig1s028, 213082Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-22","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208246s028lbl.pdf","untrusted":true}}],"fact_id":"184ac30237a50407ec400b66"},{"application":"NDA213082","submission_no":15,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-09-16","documents":[{"type":"Letter","date":"2026-09-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203214Orig1s042, 208246Orig1s028, 213082Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-22","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213082s015lbl.pdf","untrusted":true}}],"fact_id":"0137f963c0383693b82d2712"},{"application":"NDA203214","submission_no":43,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-06-30","documents":[{"type":"Letter","date":"2026-07-02","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203214Orig1s043,213082Orig1s016,208246Orig1s029ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-07-06","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s043,213082s016,208246s029lbl.pdf","untrusted":true}}],"fact_id":"83ef078de1d719a37d551457"},{"application":"NDA208246","submission_no":29,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-06-30","documents":[{"type":"Letter","date":"2026-07-02","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203214Orig1s043,213082Orig1s016,208246Orig1s029ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-07-06","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s043,213082s016,208246s029lbl.pdf","untrusted":true}}],"fact_id":"a03079b9e0a8a2186e18d731"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":5,"te_code_counts":{"AB":4,"AA":1},"marketing_status_counts":{"Prescription":5},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA203214","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XELJANZ","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"EQ 5MG BASE","untrusted":true}},{"application":"NDA203214","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XELJANZ","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"EQ 10MG BASE","untrusted":true}},{"application":"NDA208246","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XELJANZ XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"EQ 11MG BASE","untrusted":true}},{"application":"NDA208246","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XELJANZ XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"EQ 22MG BASE","untrusted":true}},{"application":"NDA213082","product_no":"001","te_code":"AA","marketing_status":"Prescription","drug_name":{"text":"XELJANZ","untrusted":true},"form":{"text":"SOLUTION;ORAL","untrusted":true},"strength":{"text":"EQ 1MG BASE/ML","untrusted":true}}]},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"TOFACITINIB","untrusted":true},"recruiting_interventional_count":28,"not_yet_recruiting_count":11,"by_phase":{"PHASE2":7,"PHASE3":4,"PHASE1":1,"PHASE4":10,"NA":5,"EARLY_PHASE1":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07281456","title":{"text":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Institute of Dental and Craniofacial Research (NIDCR)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2025-12-18","link":{"text":"https://clinicaltrials.gov/study/NCT07281456","untrusted":true}},{"nct_id":"NCT06654882","title":{"text":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Duke University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-21","start_date":"2026-01-09","link":{"text":"https://clinicaltrials.gov/study/NCT06654882","untrusted":true}},{"nct_id":"NCT07843693","title":{"text":"A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"AbbVie","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-28","start_date":"2026-08-26","link":{"text":"https://clinicaltrials.gov/study/NCT07843693","untrusted":true}},{"nct_id":"NCT04692493","title":{"text":"RA-PRO PRAGMATIC TRIAL","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"University of Alabama at Birmingham","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-24","start_date":"2021-09-22","link":{"text":"https://clinicaltrials.gov/study/NCT04692493","untrusted":true}},{"nct_id":"NCT07598643","title":{"text":"Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"University of Colorado, Denver","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-03","start_date":"2026-05-28","link":{"text":"https://clinicaltrials.gov/study/NCT07598643","untrusted":true}}],"fact_id":"b66b27e0e9f6100f557c4044"}]},"spending":{"reported_under":{"generic":{"text":"Tofacitinib Citrate","untrusted":true},"brand":{"text":"Xeljanz","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":320473730.17,"claims":66827,"beneficiaries":9966,"average_spending_per_claim_usd":4795.5726004,"fact_id":"93d7b532890e5d25592df10d"},{"year":2021,"gross_spending_usd":324605619.11,"claims":64210,"beneficiaries":9654,"average_spending_per_claim_usd":5055.3748499,"fact_id":"0e9fe7d1f54a2d327206f77a"},{"year":2022,"gross_spending_usd":295440442.38,"claims":53870,"beneficiaries":7977,"average_spending_per_claim_usd":5484.3223015,"fact_id":"ebec0d60031befdda88625c6"},{"year":2023,"gross_spending_usd":279993120.77,"claims":49575,"beneficiaries":6936,"average_spending_per_claim_usd":5647.8693045,"fact_id":"a6afb8605fd34527358bb675"},{"year":2024,"gross_spending_usd":273837700.04,"claims":48637,"beneficiaries":6688,"average_spending_per_claim_usd":5630.2341847,"fact_id":"6291dacbe1d1eadb8652e8ad"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"rems":{"programs":[{"application":"NDA203214","program":{"text":"Xeljanz","untrusted":true},"rems_id":"69","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2012-11-06","last_modified":"2016-02-08","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=69","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"5317eadfe658045e7fd37ec4"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"safety_communication":{"notices":[{"title":{"text":"Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)","untrusted":true},"issued":"2021-02-04","url":"https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis","read_on":"2026-11-07T20:11:11.310Z","fact_id":"45a2b79e46907be68f751ee4"}],"reading":"the notice as FDA published it, listed unchanged; OmniRx does not interpret it or say whether it applies to a given treatment; only the newest notice per drug is held"},"medicaid_state_utilization":{"year":2025,"states_with_data":8,"all_states_medicaid_reimbursed_usd":3463205.85,"all_states_medicaid_paid_prescriptions":575,"top_states":[{"state":"CT","medicaid_paid_prescriptions":119,"medicaid_reimbursed_usd":862105.8,"total_reimbursed_usd":862105.8,"packages":2,"covers":"all_record_types","fact_id":"1ae0442b5f071dd73f194f81"},{"state":"ND","medicaid_paid_prescriptions":99,"medicaid_reimbursed_usd":793792.44,"total_reimbursed_usd":793792.44,"packages":1,"covers":"all_record_types","fact_id":"267aceadff63f1f8464af895"},{"state":"RI","medicaid_paid_prescriptions":70,"medicaid_reimbursed_usd":408329.52,"total_reimbursed_usd":408329.52,"packages":1,"covers":"all_record_types","fact_id":"6a32a1b909fc6be6bbcb572d"},{"state":"AR","medicaid_paid_prescriptions":63,"medicaid_reimbursed_usd":327887.91,"total_reimbursed_usd":371255.49,"packages":1,"covers":"fee_for_service_only","fact_id":"34509337b2e56c41d7ea652e"},{"state":"DC","medicaid_paid_prescriptions":56,"medicaid_reimbursed_usd":311373.35,"total_reimbursed_usd":361450.89,"packages":1,"covers":"all_record_types","fact_id":"6b67308559c3a1d9aaae68de"},{"state":"MO","medicaid_paid_prescriptions":58,"medicaid_reimbursed_usd":266998.21,"total_reimbursed_usd":266998.21,"packages":1,"covers":"all_record_types","fact_id":"4e81c1670cc6da4ca503d16d"},{"state":"KY","medicaid_paid_prescriptions":54,"medicaid_reimbursed_usd":253185.16,"total_reimbursed_usd":253185.16,"packages":1,"covers":"all_record_types","fact_id":"cbc0198b37821e45180e26be"},{"state":"WA","medicaid_paid_prescriptions":56,"medicaid_reimbursed_usd":239533.46,"total_reimbursed_usd":258135.02,"packages":1,"covers":"fee_for_service_only","fact_id":"5a650640a4b255eacf58bed0"}],"unlabelled_state_code_xx":null,"built_from_facts":9,"facts_fee_for_service_only":2,"older_year_facts_not_used":113,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"6675a078ec92128d70daf33d","field":"ndc.listing","entity":"ndc:00069050130"},{"fact_id":"c94e6b3640c44861d5a3a6aa","field":"ndc.listing","entity":"ndc:00069050230"},{"fact_id":"af5f2c85e6da7931a6e35f89","field":"ndc.listing","entity":"ndc:00069100101"},{"fact_id":"a167455f17fd58fff081413b","field":"drug.generic_entry_earliest","entity":"application:NDA203214"},{"fact_id":"f489c67e11de8e126d36c3ca","field":"drug.patent","entity":"application:NDA203214"},{"fact_id":"c54dc45d2f4e31a94e56c805","field":"drug.exclusivity","entity":"application:NDA203214"},{"fact_id":"a7aadfe28d59dc11fcfa79de","field":"drug.generic_entry_earliest","entity":"application:NDA208246"},{"fact_id":"e533660bcb0acfb6f4ec26ef","field":"drug.patent","entity":"application:NDA208246"},{"fact_id":"44c6be50d91bb2f62c83c236","field":"drug.generic_entry_earliest","entity":"application:NDA213082"},{"fact_id":"2b896c18a0a2c3f1137692b3","field":"drug.patent","entity":"application:NDA213082"},{"fact_id":"e310fdd8b810420243b63f6e","field":"drug.exclusivity","entity":"application:NDA213082"},{"fact_id":"ba4c2b1ad81032eeccb6c0e1","field":"drug.label_event","entity":"application:NDA203214"},{"fact_id":"184ac30237a50407ec400b66","field":"drug.label_event","entity":"application:NDA208246"},{"fact_id":"0137f963c0383693b82d2712","field":"drug.label_event","entity":"application:NDA213082"},{"fact_id":"83ef078de1d719a37d551457","field":"drug.label_event","entity":"application:NDA203214"},{"fact_id":"a03079b9e0a8a2186e18d731","field":"drug.label_event","entity":"application:NDA208246"},{"fact_id":"f95d3dd73107cfc716a243c3","field":"drug.te_code","entity":"application:NDA203214"},{"fact_id":"ab20ee0ea8fdf32283e65467","field":"drug.marketing_status","entity":"application:NDA203214"},{"fact_id":"ebd2680393dcf036587b955a","field":"drug.te_code","entity":"application:NDA203214"},{"fact_id":"514d65a5aa05b8084b435b35","field":"drug.marketing_status","entity":"application:NDA203214"},{"fact_id":"52e090739d1d39613e8cb520","field":"drug.te_code","entity":"application:NDA208246"},{"fact_id":"ec746a4d6e8c5e9a96f5ae69","field":"drug.marketing_status","entity":"application:NDA208246"},{"fact_id":"1f213d857296c12db71d6101","field":"drug.te_code","entity":"application:NDA208246"},{"fact_id":"a0f87e83a17a175616a78a3f","field":"drug.marketing_status","entity":"application:NDA208246"},{"fact_id":"95cdb0d3f81b16c481ecd0b3","field":"drug.te_code","entity":"application:NDA213082"},{"fact_id":"72ff67efe2ac6a749f6fbd19","field":"drug.marketing_status","entity":"application:NDA213082"},{"fact_id":"b66b27e0e9f6100f557c4044","field":"drug.trial_access","entity":"drug:tofacitinib"},{"fact_id":"93d7b532890e5d25592df10d","field":"drug.partd_spending","entity":"drug:tofacitinib-citrate|xeljanz"},{"fact_id":"0e9fe7d1f54a2d327206f77a","field":"drug.partd_spending","entity":"drug:tofacitinib-citrate|xeljanz"},{"fact_id":"ebec0d60031befdda88625c6","field":"drug.partd_spending","entity":"drug:tofacitinib-citrate|xeljanz"},{"fact_id":"a6afb8605fd34527358bb675","field":"drug.partd_spending","entity":"drug:tofacitinib-citrate|xeljanz"},{"fact_id":"6291dacbe1d1eadb8652e8ad","field":"drug.partd_spending","entity":"drug:tofacitinib-citrate|xeljanz"},{"fact_id":"5317eadfe658045e7fd37ec4","field":"drug.rems","entity":"application:NDA203214"},{"fact_id":"45a2b79e46907be68f751ee4","field":"drug.safety_communication","entity":"drug:tofacitinib"},{"fact_id":"1ae0442b5f071dd73f194f81","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069100201:CT"},{"fact_id":"267aceadff63f1f8464af895","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069100101:ND"},{"fact_id":"6a32a1b909fc6be6bbcb572d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069050130:RI"},{"fact_id":"34509337b2e56c41d7ea652e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069100101:AR"},{"fact_id":"6b67308559c3a1d9aaae68de","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069050130:DC"},{"fact_id":"4e81c1670cc6da4ca503d16d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069102902:MO"},{"fact_id":"cbc0198b37821e45180e26be","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069102902:KY"},{"fact_id":"5a650640a4b255eacf58bed0","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069102902:WA"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}